What Is PT-141 (Bremelanotide)? A Clear Guide for Women
Share
PT-141, also called bremelanotide, is a lab-made peptide that acts on receptors in the brain involved in sexual desire. It is the active ingredient in Vyleesi, a medication the U.S. Food and Drug Administration (FDA) approved in 2019 to treat low sexual desire in certain premenopausal women. Unlike medications for men that work on blood flow, PT-141 works through the central nervous system; the brain pathways tied to desire itself. Because it is a prescription ingredient, it should always be used under the guidance of a licensed medical provider.
Below is a plain-language guide to what PT-141 is, how it works, what's known about its safety, and how women access it responsibly.
What is PT-141?
PT-141 (bremelanotide) is a synthetic peptide, a small, lab-made chain of amino acids modeled on a naturally occurring hormone in the body. It belongs to a class of compounds called melanocortin receptor agonists, meaning it activates a specific set of receptors in the nervous system.
Its origin is one of the more unusual stories in modern pharmacology: it was identified during research on a different peptide being studied for skin tanning, when researchers noticed an unexpected effect on sexual arousal. PT-141 was then developed to focus on that effect specifically.
How does PT-141 work?
PT-141 works in the brain, not in the bloodstream. It activates melanocortin receptors , particularly the MC4 receptor, which are found throughout the central nervous system and are thought to play a role in sexual arousal and desire. In other words, it is studied for its role in the brain's "wanting" pathways for desire, rather than the physical mechanics of blood flow.
Importantly, the precise way PT-141 produces its effects is not fully understood, even in its FDA-approved form. What is established is that its mechanism is brain-based and distinct from the medications most people associate with men's sexual health.
How is PT-141 different from men's sexual-health medications?
The well-known prescription medications for men's erectile dysfunction work primarily on blood flow; helping the body's physical response. PT-141 is fundamentally different: it acts on the brain's desire pathways. This is a meaningful distinction, because for many women the challenge isn't physical mechanics but desire itself. That's part of why PT-141 has been studied specifically in the context of low sexual desire in women, rather than borrowed from a model built around men's physiology.
Is PT-141 FDA-approved?
Yes, with an important nuance worth understanding. In June 2019, the FDA approved bremelanotide under the brand name Vyleesi, an as-needed subcutaneous (under-the-skin) injection, for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
Here's the nuance, and we'd rather be transparent about it than gloss over it: FDA approval applies to that specific finished product, Vyleesi. Compounded formulations of bremelanotide; prepared by a licensed pharmacy in a different form, such as a dissolvable tablet, are not themselves FDA-approved products. Compounding is a long-established, legal part of medicine, done under a prescribing physician's direction, but it is a different regulatory category from an FDA-approved finished drug. Any provider offering a compounded formulation should be clear with you about this, and your treatment should always involve a real medical evaluation.
What is HSDD, and is low desire "normal"?
Hypoactive sexual desire disorder (HSDD) is a recognized medical condition defined by persistently low sexual desire that causes genuine personal distress; and that isn't better explained by another medical condition, medication, or relationship issue. It has to be evaluated by a healthcare professional, who rules out other causes.
If you've experienced a drop in desire that bothers you, you are far from alone. Professional bodies in women's health have noted that a large share of women report sexual concerns at some point in their lives. The key point: changes in desire are biology, not a character flaw; and they're a legitimate thing to discuss with a qualified provider.
Why does Amorix combine PT-141 with oxytocin?
ÃœS by Amorix is formulated with two peptides: PT-141 (bremelanotide) and oxytocin. Oxytocin is a naturally occurring hormone studied for its role in bonding, trust, and emotional connection. The thinking behind pairing the two is that women's sexual experience tends to involve both a neurochemical component and an emotional one, and each ingredient has been studied in relation to a different part of that picture. To be clear, this combination is provided as a physician-prescribed, compounded formulation; it is not a guarantee of any particular result, and whether it's appropriate for you is a medical decision.
What are the possible side effects and risks of PT-141?
Like any medication that affects the body, PT-141 carries possible side effects. In the studied, FDA-approved injectable form, the most commonly reported effects were nausea (the most frequent), flushing, headache, and reactions at the injection site. The labeling also notes a transient increase in blood pressure and a decrease in heart rate after dosing, which usually resolved within hours.
Because the established safety data comes from the FDA-approved injectable product, a compounded formulation in a different form has not been evaluated by the FDA in the same way. That is exactly why a medical evaluation matters: a licensed provider reviews your health history, discusses risks with you, and determines whether treatment is appropriate. This information is educational and is not a substitute for that conversation. For content, Amorix does not carry injectables but rapid dissolvable tablets.
Who should not use PT-141?
PT-141 is not right for everyone. Based on the FDA-approved labeling, it is contraindicated for people with uncontrolled high blood pressure or known cardiovascular disease. The approved indication is specifically for premenopausal women; it was not approved for postmenopausal women or for men, and it is not intended to "enhance performance." It is also not appropriate during pregnancy or breastfeeding. Only a licensed medical provider, reviewing your individual health information, can determine whether it is safe and suitable for you.
How do women get PT-141 responsibly?
Because PT-141 is a prescription ingredient, it shouldn't be bought from gray-market or unregulated sellers. The responsible path is a medical evaluation with a licensed provider who can prescribe it when appropriate. That's how Amorix works: you begin with a confidential medical intake, our Medical Director and care team review your information, and ÃœS is prescribed and prepared individually only when a provider determines it's appropriate. Payment is an authorization only until your order is approved, you're charged only if it's approved.
This page is written to inform, not to diagnose or prescribe. If you're wondering whether PT-141 might be relevant for you, the right next step is a conversation with a medical provider.
Medically reviewed by Dr. Rafael Diaz-Yoserev, MD, FACS, Medical Director, Amorix. | This article is for general educational purposes and is not medical advice. ÃœS is a prescription product that is not appropriate for everyone, including during pregnancy or breastfeeding. Whether treatment is right for you is determined by a licensed medical provider. Amorix currently serves patients in states where its providers are licensed.
Sources: U.S. Food & Drug Administration, Vyleesi (bremelanotide injection) Prescribing Information, 2019; FDA / Palatin Technologies approval announcement, June 2019; Drugs.com Bremelanotide Professional Monograph.
